Health Law & Business News

Bipartisanship Blossoms Among House Members Through Drug Bills

April 4, 2019, 12:51 AM

In a rare moment of bipartisanship, House lawmakers on a key committee April 3 sent a handful of bipartisan bills meant to bolster drug competition to the full House floor for a vote.

The bill bundle includes two pieces of legislation that were extensively debated earlier—one that addresses drug sample access and one covering pay-for-delay tactics.

Pay-for-delay is an unlawful agreement between a brand drug maker and a generic drug maker to delay a generic version of a drug. Usually, the generic company gets some sort of payment for not pursuing a generic version in the speediest fashion.

The committee...

To read the full article log in. To learn more about a subscription click here.